Open AccessEffect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
Author(s) -
Alan P. Venook,
Doniedzwiecki,
HeinzJosef Lenz,
Federico Innocenti,
Briant Fruth,
Jeffrey A. Meyerhardt,
Deborah Schrag,
Claire Greene,
Bert H. O’Neil,
James N. Atkins,
Scott M. Berry,
Blasé N. Polite,
Eileen Mary O'Reilly,
Richard M. Goldberg,
Howard S. Hochster,
Richard L. Schilsky,
Monica M. Bertagnolli,
Anthony B. El-Khoueiry,
Peter Watson,
Al B. Benson,
Daniel Mulkerin,
Robert J. Mayer,
Charles D. Blanke
Publication year - 2017
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/9c6x-vf06
Subject(s) - cetuximab , bevacizumab , kras , medicine , oncology , colorectal cancer , chemotherapy , randomized controlled trial , clinical trial , overall survival , oxaliplatin , cancer